获取途径

作者

Jialin Zhang, Lu Lu, Wenchang Xu, Na Zhou, Yongfeng Song

作者单位

Affiliations ¹ Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Department of Endocrinology, Ministry of Education, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong Province, China. ² Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong Province, China. ³ Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong Province, China. zhounasdu@12 com. ⁴ Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Department of Endocrinology, Ministry of Education, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong Province, China. syf198506@16 com.

刊名

Cancer cell international

年份

2025

ISSN

1475-2867

关键词

Cancer Deubiquitination Immunity Inflammation Metabolism OTUD3 Pathogenesis.

摘要

OTUD3 , a deubiquitinating enzyme, has emerged as a pivotal and context-dependent regulator in cancer pathogenesis, exhibiting a striking functional duality as either a tumor suppressor or oncoprotein across different cancer types. Acting as a dual regulator, it influences key cellular processes-including proliferation, apoptosis, immune evasion, and metabolic reprogramming-by stabilizing specific substrates such as PTEN, p53, GRP78, YY1, and PD-L1. Its role extends to modulating inflammatory si...更多

OTUD3 , a deubiquitinating enzyme, has emerged as a pivotal and context-dependent regulator in cancer pathogenesis, exhibiting a striking functional duality as either a tumor suppressor or oncoprotein across different cancer types. Acting as a dual regulator, it influences key cellular processes-including proliferation, apoptosis, immune evasion, and metabolic reprogramming-by stabilizing specific substrates such as PTEN, p53, GRP78, YY1, and PD-L1. Its role extends to modulating inflammatory signaling, antiviral immunity, and metabolic homeostasis, highlighting its broad functional versatility. The development of OTUD3-targeted inhibitors like Rolapitant, Rupatadine, and OTUDin3 shows promise in preclinical models, particularly in combination with immunotherapy. However, its tissue-specific duality poses both challenges and opportunities for therapeutic intervention. Further research is needed to elucidate OTUD3's mechanistic networks and advance its clinical translation as a prognostic biomarker and therapeutic target in precision oncology.收起

文献类型

期刊

浏览量

1